Electromed, Inc. ELMD

Healthcare SIC 3845 - Electromedical & Electrotherapeutic Apparatus NAICS Manufacturing › Computer and Electronic Product Manufacturing › Navigational, Measuring, Electromedical, and Control Instruments Manufacturing derived NYSE

Electromed, Inc. ("we," "our," "us," "Electromed" or the "Company") develops, manufactures, markets and sells innovative products that provide airway clearance therapy, including the SmartVest® Airway Clearance System ("SmartVest System") to patients with compromised pulmonary function with a commitment to excellence and compassionate service. Our goal is to make High Frequency Chest Wall Oscillation ("HFCWO") treatments as effective, convenient, and comfortable as possible, so our patients can breathe easier and live better with improved respiratory function and fewer exacerbations.

We primarily employ a direct-to-patient and provider model, through which we obtain patient referrals from clinicians, manage insurance claims on behalf of our patients, and deliver the SmartVest System to patients, training them on proper use in their homes. This model allows us to directly approach patients and clinicians, whereby we disintermediate the traditional home medical equipment ("HME") channel and capture both the manufacturer and distributor margins. We also sell our products in the acute care setting for patients in a post-surgical or intensive care unit, or who were admitted for a lung infection brought on by compromised airway clearance. Electromed was incorporated in Minnesota in 1992. Our common stock is listed on the NYSE American under the ticker symbol "ELMD."

Last close 26.37 2026-10-23
Market cap $220.6M 2026-06-30 share count
52-week range 23.01 - 47.40

Valuation FY2026 figures against the last close

P/S3.0x
P/E20.3x
P/FCF26.2x
EV/EBITDA15.0x
Dividend yield—
Diluted EPS1.30

Annual financial statements

Income statement

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $73.8M$64.0M$54.7M$48.1M$41.7M$35.8M$32.5M$31.3M$28.3M$25.9M
Cost of revenue $15.8M$14.0M$13.0M$11.5M$10.2M$8.5M$7.3M$7.5M$6.5M$5.3M
Gross profit $57.9M$50.0M$41.7M$36.5M$31.4M$27.3M$25.2M$23.8M$21.8M$20.6M
R&D $1.3M$996.0K$656.0K$916.0K$1.4M$1.7M$1.1M$583.3K$251.4K$596.9K
SG&A $42.7M$39.3M$34.5M$31.6M$27.1M$22.4M$19.9M$20.4M$18.8M$16.4M
Total operating expenses $44.1M$40.3M$35.1M$32.5M$28.5M$24.2M$20.1M$21.0M$19.1M$17.0M
Operating income $13.9M$9.7M$6.6M$4.0M$3.0M$3.1M$5.1M$2.8M$2.7M$3.6M
Interest expense ——$455.0K$78.0K$25.0K$27.0K$121.0K$90.7K$19.9K$49.9K
Pre-tax income $14.4M$10.3M$7.0M$4.1M$3.0M$3.2M$5.2M$2.9M$2.7M$3.5M
Income tax $3.1M$2.7M$1.9M$920.0K$692.0K$805.0K$1.1M$940.0K$901.0K$1.3M
Net income $11.3M$7.5M$5.2M$3.2M$2.3M$2.4M$4.2M$2.0M$1.8M$2.2M
EPS, basic 1.370.890.600.370.270.280.500.240.220.27
EPS, diluted 1.300.850.580.360.260.270.470.230.210.26
Shares, diluted (wtd. avg.) 8.7M8.9M8.9M8.7M8.8M8.9M8.8M8.6M8.6M8.5M

Balance sheet

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $20.4M$15.3M$16.1M$7.4M$8.2M$11.9M$10.5M———
Receivables $29.8M$24.7M$23.3M$24.1M$21.1M$17.0M$12.9M$12.8M$11.8M$9.9M
Inventory $3.7M$3.3M$3.7M$4.2M$3.2M$2.1M$3.1M$2.6M$2.5M$2.6M
Total current assets $57.4M$45.1M$44.2M$37.8M$34.5M$31.7M$28.0M$24.5M$23.3M$18.5M
Property, plant and equipment $5.2M$4.7M$5.2M$5.7M$4.6M$3.6M$3.8M$3.6M$3.1M$3.3M
Other intangibles $379.0K$371.0K$657.0K$605.0K$599.0K$663.0K$598.0K$581.0K$649.0K$721.0K
Total assets $66.3M$53.8M$52.2M$45.8M$41.4M$37.1M$33.2M$29.4M$27.4M$23.1M
Accounts payable $2.6M$2.7M$1.0M$1.4M$1.3M$685.0K$556.0K$586.6K$810.6K$663.4K
Short-term debt —————$33.0K$72.0K$30.3K$1.1M$50.7K
Total current liabilities $12.2M$10.5M$7.7M$8.1M$7.2M$4.6M$3.0M$3.7M$4.8M$2.9M
Long-term debt —————————$1.1M
Total liabilities $12.3M$10.6M$7.7M$8.1M$7.2M$4.7M$3.0M$3.7M$4.7M$4.0M
Retained earnings $28.6M$21.2M$23.7M$18.8M$15.8M$14.9M$13.7M$9.5M$7.6M$5.0M
Total equity $54.0M$43.2M$44.5M$37.7M$34.2M$32.4M$30.2M$25.7M$22.6M$19.8M

Cash flow

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow $9.7M$11.4M$9.1M$1.3M-$686.0K$3.1M$4.2M$2.6M$2.4M$1.2M
Depreciation and amortisation $868.0K$1.0M$789.0K$550.0K$503.0K$477.0K$619.0K$804.6K$676.4K$636.7K
Stock-based compensation $2.7M$3.1M$1.7M$708.0K$976.0K$1.0M$902.0K$924.1K$862.7K$479.5K
Capital expenditure $1.3M$262.0K$287.0K$1.6M$1.4M$287.0K$844.0K$1.3M$526.2K$618.8K
Investing cash flow -$1.3M-$306.0K-$395.0K-$1.7M-$1.5M-$448.0K-$977.0K-$1.4M-$571.8K-$687.1K
Financing cash flow -$3.2M-$11.9M$36.0K-$380.0K-$1.5M-$1.2M-$548.0K-$851.2K$11.7K-$53.6K
Buybacks $3.9M$10.0M$275.0K$153.0K$1.4M$1.1M————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-028914.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 20M 40M 60M 80M Revenue, FY2017: 25.9M Gross profit, FY2017: 20.6M Net income, FY2017: 2.2M Revenue, FY2018: 28.3M Gross profit, FY2018: 21.8M Net income, FY2018: 1.8M Revenue, FY2019: 31.3M Gross profit, FY2019: 23.8M Net income, FY2019: 2M Revenue, FY2020: 32.5M Gross profit, FY2020: 25.2M Net income, FY2020: 4.2M Revenue, FY2021: 35.8M Gross profit, FY2021: 27.3M Net income, FY2021: 2.4M Revenue, FY2022: 41.7M Gross profit, FY2022: 31.4M Net income, FY2022: 2.3M Revenue, FY2023: 48.1M Gross profit, FY2023: 36.5M Net income, FY2023: 3.2M Revenue, FY2024: 54.7M Gross profit, FY2024: 41.7M Net income, FY2024: 5.2M Revenue, FY2025: 64M Gross profit, FY2025: 50M Net income, FY2025: 7.5M Revenue, FY2026: 73.8M Gross profit, FY2026: 57.9M Net income, FY2026: 11.3M FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Revenue $25.9M $28.3M $31.3M $32.5M $35.8M $41.7M $48.1M $54.7M $64.0M $73.8M
Gross profit $20.6M $21.8M $23.8M $25.2M $27.3M $31.4M $36.5M $41.7M $50.0M $57.9M
Net income $2.2M $1.8M $2.0M $4.2M $2.4M $2.3M $3.2M $5.2M $7.5M $11.3M

Recent filings and events

  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3845

TickerCompanyMarket capP/ERevenue growth
MDT Medtronic plc $122.04B 25.6x 8.4%
LIVN LivaNova PLC $4.46B — 10.7%
ITGR Integer Holdings Corp $4.30B 43.8x 8.0%
TMDX TransMedics Group, Inc. $2.45B 14.5x 37.1%
AXGN Axogen, Inc. $2.05B — 20.2%
BLFS BIOLIFE SOLUTIONS INC $1.89B — 28.9%
CNMD CONMED Corp $1.48B 32.6x 5.2%
CBLL Ceribell, Inc. $1.04B — 36.1%